Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670525 · ClinicalTrials.gov registry record · NA
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
A NA study of Recurrent, Refractory, or High Risk Leukemias and Matched Targeted Therapy, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 338
- Enrollment target
- 15
- Study locations
NCT02670525: Active NA study of Recurrent, Refractory, or High Risk Leukemias and Matched Targeted Therapy, sponsored by Dana-Farber Cancer Institute.
NCT02670525 is a NA study of Recurrent, Refractory, or High Risk Leukemias and Matched Targeted Therapy that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 338 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02670525, a NA study of Recurrent, Refractory, or High Risk Leukemias and Matched Targeted Therapy, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 338 participants
- Enrollment target
- 15
- Study locations
Study Summary
This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of physicians, scientists and pharmacists. This may result in a recommendation for a specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the participant's primary oncologist.
Primary Outcome
An actionable alteration was defined as a cancer-associated genomic event for which there was a targeted drug available. Actionable genetic alterations were identified by a combination of standard-of-care cytogenetics/fluorescence in situ hybridization (FISH) and sequencing performed as part of the study. This study is considered feasible if at least 13% of participants analyzed have profile data and identifiable actionable alterations. A 90% exact binomial confidence interval is presented for t
Conditions Studied
Interventions
- GENETIC Leukemia Profiling
Study Locations (15)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- The Children's Hospital at Montefiore - The Bronx
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- The University of Chicago - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Children's Hospital's and Clinics of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
What the registry record for NCT02670525 still lists
NCT02670525 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Recurrent, Refractory, or High Risk Leukemias appearing as the primary indexed condition, and to 1 intervention - of which Leukemia Profiling is the first listed.
NCT02670525 lists 15 locations in 12 states (New York, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT02670525 about?
NCT02670525 is a clinical study titled "Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome". This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of ...
What is the current status of trial NCT02670525?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 338 participants. The study started on 2016-08-17. Estimated completion is 2028-01-31.
What conditions does trial NCT02670525 study?
This clinical trial studies the following conditions: Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy.
What interventions are being tested in trial NCT02670525?
The interventions under investigation include: Leukemia Profiling (GENETIC).
Who is sponsoring clinical trial NCT02670525?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02670525 being conducted?
This trial has 15 study locations across California, Colorado, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02670525's enrollment target sits among peer trials
338 305th of 2000 higher than 1,696 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI